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ABSTRACT 
 
The major intracellular barriers associated with DNA delivery using non-viral vectors are 
inefficient endosomal/lysosomal escape and poor nuclear uptake. LAH4-L1, a pH responsive 
cationic amphipathic peptide, is an efficient DNA delivery vector that promotes the release of 
nucleic acid into cytoplasm through endosomal escape. Here we further enhance the DNA 
transfection efficiency of LAH4-L1 by incorporating nuclear localizing signal (NLS) to promote 
nuclear importation. Four NLSs were investigated: Simian virus 40 (SV40) large T-antigen 
derived NLS, nucleoplasmin targeting signal, M9 sequence and the reverse SV40 derived NLS. 
All peptides tested were able to form positively charged nano-sized complexes with DNA. 
Significant improvement in DNA transfection was observed in slow-dividing epithelial cancer 
cells (Calu-3), macrophages (RAW264.7), dendritic cells (JAWSII), as well as 
thymidine-induced growth-arrested cells, but not in rapidly dividing cells (A549). Among the 
four NLS-modified peptides, PK1 (modified with SV40 derived NLS) and PK2 (modified with 
reverse SV40 derived NLS) were the most consistent in improving DNA transfection; up to a 
10-fold increase in gene expression was observed for PK1 and PK2 over the unmodified 
LAH4-L1. Additionally PK1 and PK2 were shown to enhance cellular uptake as well as nuclear 
entry of DNA. Overall, we show that the incorporation of SV40 derived NLS, in particular, to 
LAH4-L1 is a promising strategy to improve DNA delivery efficiency in slow-dividing cells and 
dendritic cells, with development potential for in vivo applications and as a DNA vaccine carrier.  
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INTRODUCTION 
 
Despite the huge therapeutic potential of gene therapy including DNA vaccines, its clinical 
application is currently limited by the lack of a safe and effective delivery system. Non-viral 
vectors have the advantages of better safety profile and lower production cost compared to their 
viral counterparts, but their transfection efficiency is generally low.
1, 2
 In order for therapeutic 
gene to function, plasmid DNA encoding the protein of interest must be delivered to the nucleus 
of the target cells to allow the transcription of DNA into the messenger RNA (mRNA), which is 
subsequently translated into the therapeutic proteins. DNA is a negatively charged, hydrophilic 
macromolecule with poor membrane permeability and is susceptible to nuclease degradation. 
Most non-viral vectors such as polymers, lipids and peptides are able to condense DNA to 
nanosize scale, either as complexes or nanoparticles, to protect the nucleic acids from 
degradation and facilitate cellular uptake through endocytosis.
1, 3, 4
 Upon cell entry, non-viral 
delivery systems usually face two major intracellular barriers: (i) endosomal/lysosomal 
degradation; and (ii) poor nuclear entry. Therefore, the efficiency of a non-viral vector highly 
depends on its ability to promote endosomal/lysosomal escape and nuclear uptake. In addition, it 
is crucial that the DNA can be released or unloaded efficiently from the carrier so that it can be 
properly expressed, and the carrier itself must be non-toxic and biocompatible. 
 
For most non-viral vectors, nuclear entry is an extremely inefficient process which limits their 
transfection efficiency.
1, 5, 6
 Only when the cells are undergoing mitosis does the nuclear 
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envelope break down so that the permeability barrier to the nucleus is temporarily lost and 
nuclear entry can be achieved by passive diffusion.
7
 Since DNA is too large to be passively 
transported, the only way to enter the intact nucleus of non-dividing cells is by active transport 
through the nuclear pore complex (NPC). This process usually requires the assistance of a 
nuclear localization signal (NLS), which facilitates the active transport of macromolecules into 
the nucleus from the cytoplasm through binding to nuclear transport proteins.
8
 Different types of 
NLS have been reported to enhance the nuclear uptake of macromolecules. In general, NLS can 
be categorized as classical and non-classical. The former typically contains a series of basic, 
positively charged amino acid sequence while the latter does not, and they differ in binding 
affinity to different nuclear transport receptors.
6, 8
 
 
The most widely studied classical NLS is the Simian Virus 40 (SV40) large T-antigen-derived 
NLS,
9-11
 a monopartite NLS that contains a single stretch of basic amino acids. It is also the most 
commonly investigated NLS for the delivery of macromolecules with a well-defined nuclear 
import pathway. In the cytoplasm, the SV40 derived NLS is linked to the macromolecule and is 
recognized by the α-subunit of the importin α/β heterodimer. The β-subunit mediates the 
interaction with the NPC to facilitate the translocation of the trimeric complex into the nucleus.
3, 
6, 12-14 
Other classical NLSs include the nucleoplasmin targeting signal, which is a representative 
of bipartite NLSs and contains two interdependent basic amino acid clusters separated by 10 
intervening neutral amino acids. Similar to SV40 derived NLS, the nucleoplasmin targeting 
signal also facilitates the nuclear entry of macromolecules by the importin α/β heterodimer.
6, 8, 13, 
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15
 In contrast, the non-classical NLSs lack the stretches of basic amino acid and they mediate the 
nuclear uptake through a different mechanism. The best-known example of non-classical NLS is 
the M9 sequence from the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1).
13, 16 
The 
M9 sequence facilitates the transport of macromolecules across the NPC through binding to the 
transportin, an endogenous carrier protein distinct from the importin-mediated pathway.
16, 17
 The 
use of NLSs to promote nuclear importation and enhance gene delivery has been reported in 
various non-viral gene delivery vectors including cationic polymers,
18-20
 oligopeptides
21
 and cell 
penetrating peptides.
22, 23
  
 
Previously, our group and others have reported the use of LAH4-L1 peptide for DNA and siRNA 
delivery.
24-28
 LAH4-L1 is a histidine-rich, cationic amphipathic peptide with pH responsive 
properties. At pH 7, the LAH4-L1 binds with and condenses DNA to form nano-sized complexes 
which enter cells through endocytosis. Once inside the acidic endosomes, LAH4-L1 becomes 
protonated and this causes a release of a substantial proportion of the peptide from the complex 
with a concomitant switch from an alpha-helical conformation to a disordered conformation in 
solution. The disordered LAH4-L1 is capable of binding and inserting into the endosomal 
membrane where it again adopts a surface aligned alpha-helix conformation capable of 
disordering the endosomal membrane and promoting endosomal escape of the remaining 
complexes.
29, 30
 To further improve the DNA delivery efficiency of LAH4-L1, the strategy of 
incorporating NLS to the delivery peptide was explored to enhance nuclear entry. In this work, 
three different NLS sequences were employed: (i) the classical SV40 derived NLS; (ii) the 
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classical nucleoplasmin NLS; and (iii) the non-classical M9 NLS. Four NLS-modified LAH4-1 
peptides, namely PK1-LAH4-L1 (PK1), PK2-LAH4-L1 (PK2), KR-LAH4-L1 (KR) and 
NQ-LAH4-L1 (NQ) (Table 1) were evaluated for their DNA binding affinity, transfection 
efficiency and the ability to promote nuclear entry. Their biological activities were tested and 
compared on various cell types, including A549 and Calu-3 cells which are human airway 
epithelial cells; RAW264.7 cells which are murine macrophage-like cells; and JAWS II cells 
which are murine immature dendritic cells. Furthermore, the transfection efficiency of the 
peptides was evaluated on A549 cells at growth-arrested state. 
 
EXPERIMENTAL SECTION 
 
Materials. All peptides investigated in this study (Table 1) were purchased from ChinaPeptides 
(Shanghai, China) at >70% purity and were used as provided. Dulbecco's modified eagle 
medium (DMEM), DMEM/F-12 medium, α-minimum essential medium (MEM α, nucleosides), 
Opti-MEM I reduced serum medium, antibiotic–antimycotic liquid, 0.25% Trypsin-EDTA, fetal 
bovine serum (FBS, South America origin), Lipofectamine™ 2000, Lysotracker Green DND-26 
and Hoechst Stains 33258 were purchased from Invitrogen (New York or Carlsbad, USA). 
Recombinant murine granulocyte–macrophage colony stimulating factor (GM-CSF) was 
purchased from Peprotech (Rocky Hill, NJ, USA). The luciferase assay system was purchased 
from Promega (Madison, WI, USA). GelRed™ nucleic acid stain was purchased from Biotium 
(Hayward, CA, USA). Plasmid DNA (gWIZ™ Luciferase) was purchased from Aldevron (Fargo, 
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ND, USA). Label IT® CX-Rhodamine nucleic acid labeling kit was purchased from Mirus Bio 
(Madison, WI, USA). The lactate dehydrogenase (LDH) cytotoxicity assay kit was purchased 
from Cayman Chemical Company (Ann Arbor, MI , USA). 1 × Tris-acetate EDTA (TAE) buffer 
was diluted from 50 × TAE buffer (242 g/L Tris base, 57.1 ml/L glacial acetic acid and 37.2 g/L 
EDTA, pH 8.5) using distilled water. All other reagents were obtained from Sigma Aldrich 
(Saint Louis, MO, USA) and of analytical grade or better. 
 
Table 1. Sequence, molecular weight (MW), hydrophobicity, net charge and percentage charged residue 
of the LAH4-L1 and NLS-modified peptides. The NLS sequences are highlighted in bold and the linker 
group is underlined. The hydrophobicity is calculated according to the Eisenberg Consensus scale.
31
  
Peptide NLS Sequence 
MW 
(Da) 
Average 
hydrophobicity 
Net charge at pH 7 
(% charged 
residue) 
LAH4-L1 - 
KKALLAHALHLLALLALHL
AHALKKA-NH2 
2778 -0.05 
+5.4 
(20.8) 
PK1-LAH4-L1 
(PK1) 
SV40 
PKKKRKVGCGKKALLAHA
LHLLALLALHLAHALKKA-
NH2 
3861 -0.11 
+10.3 
(28.6) 
PK2-LAH4-L1 
(PK2) 
‘Reversed’ 
SV40 
VKRKKKPGCGKKALLAHA
LHLLALLALHLAHALKKA-
NH2 
3861 -0.11 
+10.3 
(28.6) 
KR-LAH4-L1 
(KR) 
Nucleoplasmin 
KRPAATKKAGQAKKKKG
CGKKALLAHALHLLALLAL
HLAHALKKA-NH2 
4717 -0.17 
+13.3 
(29.6) 
NQ-LAH4-L1 
(NQ) 
M9 
NQSSNFGPMKGGNFGGRS
SGPYGGGGQYFAKPRNQG
GYGCGKKALLAHALHLLAL
LALHLAHALKKA-NH2 
6863 -0.08 
+9.3 
(13.9) 
Page 7 of 39
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8 
 
 
Gel retardation assay. For DNA binding assay, peptide/DNA complexes were prepared at 2:1, 
5:1, 10:1 and 15:1 ratios (w/w) with 1 µg luciferase DNA in 25 µl TAE buffer. After leaving the 
complexes for 30 min at room temperature, 10 µl of samples were loaded into an agarose gel 
(1% w/v) stained with GelRed™. Gel electrophoresis was run in TAE buffer at 120 V for 45 min 
and the gel was visualized under the UV illumination. For DNA release assay, the peptide/DNA 
complexes were prepared at 5:1 and 10:1 ratios (w/w) as described. After 30 min, 5 µl of sodium 
dodecyl sulphate (SDS) solution (5 mM) was added to the complexes to allow the release of 
DNA. The mixtures were incubated at room temperature for 1 h. The samples were then loaded 
into a 1% w/v agarose gel and electrophoresis was run as described earlier. Untreated DNA and 
SDS treated DNA were used as controls. 
 
Particle size and zeta potential measurement. For size measurement, peptide/DNA complexes 
were prepared at 10:1 ratio (w/w) with 4 µg luciferase DNA in 100 µl ultrapure water. After 
leaving the mixture for 30 min at room temperature, the hydrodynamic diameter and the 
polydispersity index of the complexes were measured by photon correlation spectroscopy 
(Delsa
TM
-Nano C, Beckman Coulter, CA, USA). For zeta potential measurement, the 
peptide/DNA complexes were prepared at 10:1 ratio (w/w) with 20 µg luciferase DNA in 500 µl 
of 2% PBS. The mixture was then incubated at room temperature for 30 min and the zeta 
potential was measured in a flow cell using electrophoretic light scattering (Delsa
TM
-Nano C, 
Beckman Coulter, CA, USA). 
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Morphology study.  The peptide/DNA complexes were prepared at 10:1 ratio (w/w) with 2 µg 
luciferase DNA in 200 µl ultrapure water and the complexes were left at room temperature for at 
least 30 min. A drop of sample (around 30 µl) was placed onto a discharged copper grid coated 
with carbon-formvar for 30 s, followed by staining with 4% (w/v) uranyl acetate for 1 min. The 
grid was then washed with distilled water once. Excessive solution was carefully removed by 
filter paper prior to air-drying. The samples were analyzed under the transmission electron 
microscope (TEM) (Philips CM100 TEM, Philips Electron Optics, Eindhoven, Netherlands) at a 
voltage of 100 kV. Micrographs were taken using a digital camera (Olympus, TENGRA 2.3K × 
2.3K bottom mounted camera system with iTEM acquisition software).  
 
Cell culture. A549, Calu-3, RAW 264.7 and JAWSII cells were obtained from American Type 
Culture Collection (Manassas, VA, USA). Calu-3 cells were grown in DMEM/F-12 medium 
supplemented with 10% v/v FBS and were subcultured once a week; A549 and RAW264.7 cells 
were grown in DMEM supplemented with 10% FBS and were subcultured every three days; 
JAWSII cells were cultured in α-minimum essential medium supplemented with 20% v/v FBS 
and 5 ng/ml recombinant mouse granulocyte–macrophage colony stimulating factor (GM-CSF) 
and were subcultured once a week. All the media contained 1% v/v antibiotic/antimycotic liquid 
and all the cells were maintained at 37°C, 5% CO2. 
 
Page 9 of 39
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 
 
DNA transfection. A549, Calu-3, RAW264.7 and JAWSII cells were transfected with 
peptide/DNA complexes at 1 µg luciferase plasmid per well in 24-well plates. Lipofectamine™ 
2000 was used as control. The complexes were prepared at 5:1, 10:1 and 15:1 ratios (w/w) in 
Opti-MEM I reduced serum medium. The cells were transfected when they reached 70-80% 
confluency. After 5 h of incubation with the complexes at 37 °C, the transfection media were 
removed and replaced with serum supplemented cell culture media. At 24 h post-transfection, the 
cells were rinsed and lysed in 100 µl reporter lysis buffer. The luciferase expression was detected 
using the luciferase assay system according to the manufacturer's protocol. The results were 
expressed as relative light unit (RLU) per mg of total protein. For transfection with 
growth-arrested cells, the standard double thymidine block method was employed as previously 
reported.
32
 A549 cells were seeded at a density of 5 × 10
4
 cells per well in 24-well plate for 
overnight. The cell culture medium was then replaced with one containing thymidine (2mM). 
After 19 h of incubation, the cells were washed and incubated with thymidine-free culture 
medium. After 9 h, thymidine was added to the culture medium and the cells were incubated for 
a further 17 h. The cells were washed again. Peptide/DNA complexes prepared in Opti-MEM I 
reduced serum medium containing thymidine were added to the cells. After 5 h of incubation, the 
transfection medium was removed and replaced with fresh culture medium. The luciferase 
expression was examined at 24 h post-transfection as described above.  
 
Cellular uptake assay. DNA was fluorescently labelled with rhodamine using the Label IT
®
 
CX-Rhodamine nucleic acid labeling kit, which is commonly used for intracellular trafficking 
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studies of gene delivery system,
18, 33
 according to the manufacturer’s protocol. Calu-3, 
RAW264.7 and JAWSII cells were seeded onto 6-well culture plates at a seeding density of 4 × 
10
5
 cells per well. After 24 to 48 h, the cells were washed with PBS and transfected with 
peptide/DNA complexes (prepared at 10:1 ratio w/w) containing 2 µg of labelled DNA per well 
in Opti-MEM Ι reduced serum medium. After 5 h of incubation, the transfection medium was 
removed and the cells were washed with warm PBS. The cells were then detached from the 
plates using 0.25% w/v Trypsin-EDTA or 0.02% w/v EDTA-EGTA in PBS. To quench the 
extracellular fluorescence signal, trypan blue solution (0.04% w/v) prepared in PBS was added to 
the cells for 2 min. The cells were then centrifuged and washed with PBS thrice. The cells were 
re-suspended in 500 µl PBS and sieved with a sterile 40 µm cell strainer (BD Biosciences, CA, 
USA). The fluorescence intensity of the transfected cells was analyzed by flow cytometer (BD 
LSR Fortessa Analyzer, BD Bioscience, USA). The cells were gated electronically according to 
the non-transfected cell forward-scatter (FSC) and side-scatter (SSC) properties to induce the 
main population of cells and to exclude dead cells. At least 10,000 events were analyzed for each 
sample. The results were expressed as percentage of cells displayed positive fluorescence signal 
compared to the untreated cells. The mean fluorescence intensity of the treated cells was also 
calculated and compared. 
 
Nuclear uptake assay. The nuclear isolation and DNA quantification method was adopted from 
previous studies with modification.
21, 34, 35
 RAW264.7 and JAWSII cells were seeded onto 6-well 
plates at a seeding density of 5 × 10
5
 cells per well for overnight. The cells were washed with 
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PBS and transfected with peptide/DNA complexes (prepared at 10:1 ratio w/w) containing 2 µg 
of rhodamine labelled DNA per well in Opti-MEM Ι reduced serum medium. After 5 h, the 
transfection medium was removed and replaced with serum-supplemented culture media. The 
cells were washed with PBS and detached from the plates at 24 h post-transfection using 
EDTA-EGTA (0.02% w/v). To collect the cell nuclei, the cells were incubated in hypotonic 
buffer (10 mM KCl, 1.5 mM MgCl2, 10 mM HEPES, pH 7.4) on ice for 10 min. 500 µl lysis 
buffer (1% v/v Nonidet P-40, 10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2, pH7.4) were added 
to the cells. The mixtures were vortexed for 5 to 10 s and incubated for 2 min at room 
temperature to dissolve the cell membranes. The lysis of cell membrane and the maintenance of 
nuclear integrity were monitored under a microscope. After centrifugation at 1,400 × g for 5 min, 
the supernatant (cytosolic fraction) was removed and the pellets (nuclear fraction) were washed 
with PBS and re-suspended in 500 µl PBS for nuclei counting and fluorescence detection. The 
number of nuclei was counted using a hemocytometer after staining with 0.5% Trypan Blue 
solution in PBS (v/v). The fluorescent intensity of the labelled DNA in the nuclei was analyzed 
by a fluorescent microplate reader (CLARIOstar
®
, BMG Labtech, Germany). The amount of 
labelled DNA in the nuclei was calculated using a standard curve and the results were shown as 
the amount of DNA per nucleus. 
 
Confocal live cell imaging. Calu-3 cells were seeded on a 35 mm Mattek glass bottom culture 
dish (Mattek Corp. Ashland, MA) with 4 × 10
5
 cells per well for overnight. Peptide/DNA 
complexes (10:1 ratio w/w) were prepared using rhodamine labelled DNA in 1 ml of Opti-MEM 
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I reduced serum medium and were added to the cells after 30 min of incubation. The complexes 
were removed and replaced with serum-supplemented culture medium after 5 h of incubation. 
The cells were imaged at 24 h post-transfection. Prior to imaging, the nuclei of the cells were 
stained with Hoechst (5 µg/ml) for 30 min. The lysosomes were labelled with Lysotracker (50 
nM) 2 min before imaging. During live cell imaging, the cells were incubated at 37 °C and 5% 
CO2 in a heated stage-top incubator. The confocal laser scanning microscope (Zeiss LSM 780 
inverted microscope, Jena, Germany) with diode laser (405 nm), argon laser (488 nm) and 
diode-pumped solid state (DPSS) laser (561 nm) were used to visualize the cells. The 
microscope was observed with 40 × 1.4 oil DIC objective lens. The images were analyzed by 
Zeiss LSM Image Browser (Version 8.1.0.484, Jena, Germany). 
 
Cytotoxicity study. Calu-3 and JAWSII cells were seeded in 96-well plates at a cell density of 4 
× 10
4 
cells per well for 48 h. Peptide/DNA complexes (prepared at 10:1 ratio w/w) containing 0.5 
µg luciferase plasmid per well were diluted in 200 µl of culture medium. Triton X-100 (1% v/v) 
treated cells and untreated cells were used as positive and negative controls respectively under 
the same condition. At 5 h post-transfection, 100 µl cell supernatant from each well was 
transferred to a new 96-well plate and the LDH activity was determined using LDH cytotoxicity 
assay kit according to the manufacturer’s protocol. The relative LDH release was calculated by 
the percentage of LDH release in the sample over control, with 1% Triton X-100 treated cells 
were set as 100% LDH release and the untreated cells were set as 0% LDH release. 
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RESULTS 
 
DNA affinity. The peptides were evaluated for their affinity to DNA. In the DNA binding study 
(Fig. 1), the shift or disappearance of DNA band in the gel indicated binding occurred between 
DNA and peptides. For LAH4-L1 and NQ, DNA binding was observed at 5:1 ratio (w/w) 
onwards, whereas for PK1, PK2 and KR, DNA binding was detected at a lower ratio of 2:1 
(w/w), suggesting that PK1, PK2 and KR had higher DNA affinity than LAH4-L1 and NQ. In 
the DNA release study, the anionic surfactant SDS was used to dissociate the peptide/DNA 
complexes by competing with DNA for the cationic peptides (Fig. 2). Since all the peptides 
could bind to DNA at ratio 5:1 (w/w) or above, the recovery of DNA band in the gel suggested 
that the DNA could be released from the complexes by SDS. For LAH4-L1, PK1 and PK2, the 
release of DNA was observed at 5:1 and partially at 10:1 ratios (w/w), whereas for KR, the 
partial release of DNA was only observed at 5:1 ratio (w/w). The binding between KR and DNA 
at ratio 10:1 (w/w) was probably too strong to be released by the SDS, suggesting that KR had 
the highest DNA affinity. Overall, the DNA affinity of the peptides was in the descending order 
of KR > PK1 and PK2 > LAH4-L1 and NQ.  
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Figure 1. Agarose gel retardation assay of DNA binding. Peptide/DNA complexes were prepared at 2:1, 
5:1, 10:1 and 15:1 ratios (w/w). Naked DNA (N) were used as controls. At 30 min after complex 
formation, the samples were loaded into the agarose gel (1% w/v) stained with GelRed™. Electrophoresis 
was carried out at 120 V for 45 min and the gel was visualized under the UV illumination. 
 
 
Figure 2. Agarose gel retardation assay of DNA release. Peptide/DNA complexes were prepared at 5:1 
and 10:1 ratios (w/w). At 30 min after complex formation, SDS (5 mM) was added to allow dissociation 
of complexes. After 1 h, the mixtures were loaded into an agarose gel (1% w/v) stained with GelRed™. 
Naked DNA (N) and SDS treated DNA (S) were used as controls. Electrophoresis was carried out at 120 
V for 45 min and the gel was visualized under the UV illumination.  
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Particle size and zeta potential analysis. The particle size distribution and the zeta potential of 
peptide/DNA complexes prepared at 10:1 ratio (w/w) were determined by photon correlation 
spectroscopy and electrophoretic light scattering, respectively (Table 2). All the peptides formed 
nano-sized complexes with DNA ranging from 130 nm to around 350 nm. The polydispersity 
index of the complexes was similar, ranging between 0.19 and 0.27. Among these complexes, 
those formed with PK1, PK2 and KR were below 200 nm, and they were smaller than the 
complexes formed with LAH4-L1, which were over 200 nm. NQ formed the largest DNA 
complexes which were over 300 nm. For zeta potential measurement, all the complexes formed 
were positively charged. Complexes formed with KR had the highest zeta potential of around 
+24 mV, followed by PK1 and PK2 which had the zeta potential between +10 to +13 mV. The 
complexes formed with LAH4-L1 were only slightly positive charged with a zeta potential value 
of +2 mV.  
 
Table 2. Hydrodynamic diameter, polydispersity index and zeta potential of peptide/DNA complexes 
prepared at 10:1 ratio (w/w) measured by photon correlation spectroscopy and electrophoretic light 
scattering (n=4). (N.A. data not available due to insufficient material) 
Peptides Diameter ± SD (nm) 
Polydispersity index ± 
SD 
Zeta Potential ± SD 
(mV) 
 LAH4-L1 226.7 ± 31.7 0.24 ± 0.05 +2.2 ± 0.9 
PK1 164.9 ± 1.3 0.27 ± 0.02 +10.1 ± 2.1 
PK2 130.1 ± 1.1 0.26 ± 0.01 +13.3 ± 1.6 
KR 184.6 ± 6.8 0.27 ± 0.02 +24.2 ± 0.9 
NQ 354.5 ± 81.5 0.20 ±0.01 N.A. 
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Morphology study. The morphology of peptide/DNA complexes was examined by TEM (Fig. 
3). As shown in the microscope images, all the peptides investigated (LAH4-L1, PK1, PK2 and 
KR) were able to form nano-sized, compact but irregularly shaped complexes with DNA, and the 
morphology of the complexes formed with different peptides were all very similar. 
 
 
Figure 3. TEM images of peptide/DNA complexes - LAH4-L1/DNA complexes (A); PK1/DNA 
complexes (B); PK2/DNA complexes (C); KR/DNA complexes (D). All the complexes were prepared at 
10:1 ratio (w/w) in ultrapure water and stained with 4% (w/v) uranyl acetate. Scale bar = 200 nm 
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Luciferase DNA transfection efficiency. DNA delivery efficiency was examined by luciferase 
activity on four different cell lines after transfected with peptide/DNA complexes prepared at 5:1 
to 15:1 ratios (w/w) (Fig. 4). Comparing to LAH4-L1, none of the NLS-modified peptides 
showed significant improvement of transfection on A549 cells. PK1 and PK2 were able to 
improve DNA transfection efficiency significantly over the LAH4-L1 (p < 0.05) on other three 
cell lines. On Calu-3 cells, both peptides showed approximately 9-fold increase in transfection 
efficiency over LAH4-L1 at 10:1 ratio (w/w). On RAW264.7 cells, significant improvement was 
observed at all three ratios, with the largest increase by around 6-fold at 5:1 ratio (w/w) for both 
PK1 and PK2. On JAWSII cells, there was up to 5.5- to 6.0-fold increase in transfection 
efficiency over LAH4-L1 for PK1 and PK2 at 10:1 ratio (w/w). KR was able to improve DNA 
transfection efficiency of LAH4-L1 significantly (p < 0.05) on JAWSII cells (at 10:1 and 15:1 
ratios w/w) only, with up to 9.4-fold of increase in gene expression observed at 10:1 ratio (w/w). 
KR also mediated transfection on RAW264.7 cells about one-fold higher than LAH4-L1, but the 
change was not statistically significant. NQ failed to improve the transfection over LAH4-L1 on 
all four tested cell lines. In addition, PK1, PK2 and KR (at 10:1 and 15:1 ratios w/w) also 
performed significantly better than Lipofectamine™ 2000 (p < 0.05) on JAWSII cells. For 
transfection on growth-arrested cells (Fig. 5), A549 cells were kept at non-dividing state by 
double thymidine block. A significant improvement in transfection was observed with PK1 
peptide (p < 0.01) and PK2 (p < 0.001), with around 1.4-fold and 1.7-fold of increase in gene 
expression respectively compared to LAH4-L1. However, KR failed to mediate DNA 
transfection when A549 cells were non-dividing.  
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Figure 4. Luciferase DNA transfection study. Cells were transfected with peptide/DNA complexes 
prepared at 5:1, 10:1 and 15:1 ratios (w/w), with 1 µg DNA per well in 24-well plates. Luciferase 
expression was measured at 24 h post-transfection. Lipofectamine™ 2000 (lipid/DNA 2:1 ratio w/w) was 
used as control. Transfection was carried out on A549 cells (A); Calu-3 cells (B); RAW264.7 cells (C); 
and JAWSII cells (D). The data were analyzed by one-way ANOVA followed by Bonferroni post-hoc test. 
* (p < 0.05); ** (p < 0.01); *** (p<0.001) compared with LAH4-L1 at the same ratio (w/w); 
# 
(p < 0.05); 
## 
(p < 0.01); 
###
 (p<0.001) compared with Lipofectamine 2000. Values are the mean ± SEM (n=3-4). 
  
B 
C 
A 
D 
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Figure 5. Luciferase DNA transfection study on growth-arrested A549 cells. The cells were kept in 
growth-arrested state (non-dividing) using double thymidine block. Cells were transfected with 
peptide/DNA complexes prepared at 10:1 ratio (w/w), with 1 µg DNA per well in 24-well plates. 
Expression of luciferase was measured at 24 h post-transfection. The data were analyzed by one-way 
ANOVA followed by Bonferroni post-hoc test. ** (p < 0.01); ***(p < 0.001) compared with LAH4-L1. 
Values are the mean ± SEM (n=4). 
  
Cellular uptake study. The cellular uptake of fluorescently labelled DNA was measured by 
flow cytometry (Fig. 6). A549 cells were not used because none of the NLS-modified peptides 
showed significant improved transfection on this cell line when the cells are dividing. NQ, which 
failed to show any increase in transfection over LAH4-L1 in any of the cell lines, was also 
excluded. The peptide/DNA complexes were prepared at 10:1 ratio w/w. The histogram analysis 
(Fig. 6 A-C) showed the fluorescent-positive cell populations in percentage (shaded) as 
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compared to the fluorescent-negative untreated control (unshaded). PK1, PK2 and KR all 
showed a higher percentage of fluorescent-positive cells than LAH4-L1 in all three cell lines. A 
similar trend was observed when compared the mean fluorescence intensity of the treated cells 
(Fig. 6 D-F). The three NLS-modified peptides showed significant increase (p < 0.05) in 
fluorescence intensity over Lipofectamine 2000 and LAH4-L1 on JAWSII cells, but not on the 
other two cell lines.  
 
 
 
A 
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Figure 6. Cellular uptake study of fluorescently labelled DNA by flow cytometry. Cells were transfected 
with peptide/DNA complexes prepared at 10:1 ratio (w/w) at 2 µg per well in 6-well plates. Naked DNA 
and Lipofectamine 2000 (lipid/DNA at 2:1 ratio w/w) were used as controls. Transfection was carried out 
on Calu-3 cells (A & D); RAW264.7 cells (B & E); and JAWSII cells (C & F). The mean fluorescence 
intensity of the cells was measured at 5 h post-transfection. The histograms of fluorescence intensity and 
the percentage of cells that displayed positive fluorescence signal (shaded) compared to untreated cells 
(unshaded) were shown (A-C). The fluorescence intensity was also expressed as fold change compared to 
the untreated cells (D-F). The data was analysed by one-way ANOVA followed by Bonferroni post-hoc 
test. * (p < 0.05) compared with LAH4-L1 at the same ratio (w/w); 
#
 (p < 0.05); 
## 
(p < 0.01) compared 
with Lipofectamine 2000. Values are the mean ± SEM (n=3-4).   
  
Nuclear import study. The nuclear uptake of fluorescently labelled DNA was quantified in the 
isolated nuclei of the cells after they were transfected using LAH4-L1, PK1 or PK2 (Fig. 7). Due 
to the highly aggregating nature of Calu-3 cells
36
 which often led to incomplete cell lysis during 
the nuclei isolation process, this study was carried out on RAW264.7 and JAWSII cells only (the 
live cell confocal imaging was used to visualize the nuclear localization in Calu-3 cells). Similar 
to the cellular uptake study, the peptide/DNA complexes were prepared at 10:1 ratio (w/w). Both 
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PK1 and PK2 were able to enhance the transportation of DNA into the nucleus significantly (p < 
0.05) on both RAW264.7 and JAWSII cells when compared to LAH4-L1. In addition, PK1 and 
PK2 also mediated higher nuclear uptake of DNA over Lipofectamine™ 2000.  
 
   
Figure 7. Nuclear uptake study of DNA. Fluorescently labelled DNA was used to prepared peptide/DNA 
complexes at 10:1 ratio (w/w) at 2 µg per well in 6-well plates. Naked DNA and Lipofectamine™ 2000 
(lipid/DNA 2:1 ratio w/w) were used as controls. Transfection was carried out on RAW264.7 cells (A) 
and JAWSII cells (B). At 24 h post-transfection, cell nuclei were isolated and the amount of labelled 
DNA was quantified by measuring the fluorescence level compared to a standard curve. The data was 
compared and analyzed by one-way ANOVA followed by Bonferroni post-hoc test. *(p<0.05) and 
**(p<0.01) compared to cells transfected with LAH4-L1; 
### 
(p<0.001) compared to cells transfected with 
Lipofectamine 2000. Values are the mean ± SEM (n=4).  
  
Live cell confocal imaging. The localization of exogenous DNA delivered by LAH4-L1 and 
PK2 was compared on Calu-3 cells (Fig. 8). The DNA was fluorescently labelled with 
rhodamine (red), the nuclei were stained with Hoechst 33258 (blue), and the lysosomes were 
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labelled with LysoTracker (green). The cells were imaged at 24 h post-transfection by live cell 
imaging. The nuclear localization of exogenous DNA was observed in cells transfected with PK2, 
as indicated by the arrows in the image (Fig. 8H), but not in LAH4-L1. Moreover, the 
co-localization between DNA and lysosomes (as seen in yellow) was observed with cells 
transfected with LAH4-L1 but not with those transfected with PK2.  
 
 
Figure 8. Localization of DNA using confocal live cell imaging. Calu-3 cells were transfected with DNA 
using LAH4-L1 (A-D) or PK2 (E-H), and the peptide/DNA complexes were prepared at 10:1 ratio (w/w). 
The images were taken at 24 h post-transfection. Luciferase DNA (red) was labelled with rhodamine (A 
& E); LysoTracker (green) was used to label the lysosomes (B & F); the nuclei (blue) were stained with 
Hoechst (C & G) and the overlaid images were shown (D & H). The white arrows indicate the 
co-localization of DNA and nucleus. Scale bar = 10 µm. 
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Cytotoxicity study. The cytotoxicity of peptide/DNA complexes on Calu-3 and JAWSII cells 
was evaluated by LDH assay (Fig. 9). No sign of toxicity was observed in Calu-3 cells after 
exposure to the complexes, suggesting that the peptides were not toxic to epithelial cells at 
concentration used for transfection. For JAWSII cells, there was no sign of toxicity in cells 
treated of NLS-modified peptide/DNA complexes, and just below 20% of LDH release was 
observed in cells treated with LAH4-L1/DNA complexes. The results suggested that LAH4-L1 
appeared to be more cytotoxic than the NLS-modified peptides in dendritic cells. 
 
 
Figure 9. Cytotoxicity study using lactate dehydrogenase (LDH) release assay on Calu-3 and JAWSII 
cells. Peptide/DNA complexes were prepared at 10:1 w/w ratio at 0.5 µg per well in 96-well plates. Triton 
X-100 (1% v/v) were used as positive controls. LDH assay was carried out at 5 h post-transfection. 
Results were presented as percentage of LDH release relative to the controls (Triton X-100 treated cells 
were set as 100% LDH release and the untreated cells were set as 0% LDH release). The bars were shown 
as mean ± SEM (n=3-4).  
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DISCUSSION 
 
Nuclear entry is a major hurdle to effective DNA delivery. One of the strategies to overcome this 
barrier is by incorporation of NLS to the delivery system. It was previously demonstrated that 
LAH4-L1, a pH responsive peptide, was able to mediate effective transfection of nucleic acids in 
mammalian cells.
24
 In this study, LAH4-L1 was modified with NLS with the attempt to further 
improve the transfection efficiency by enhancing the nuclear uptake of DNA. The advantage of 
attaching the NLS to the carrier instead of the DNA directly is to avoid any possible interference 
with the transcription domain of the DNA,
37, 38
 as well as the more flexible application to 
different kinds of genes. Here, three NLSs were investigated, including two classical NLSs 
(SV40 derived NLS and nucleoplasmin targeting signal) and one non-classical NLS (M9 
sequence). In addition, the reverse SV40 derived NLS was also examined. A simple construct 
was employed, with NLS attached to the N terminal of LAH4-L1 and a short glycine-rich linker 
(GCG) in between to separate the two domains. 
 
LAH4-L1 carries a net positive charge, which allows it to form complexes with the negatively 
charged DNA through electrostatic interaction. The classical NLSs typically contain series of 
positively charged amino acid residues, therefore the addition of this type of NLS leads to an 
increase of overall charge of the peptide. Due to the difference in charge density between the 
four NLS-modified peptides, their affinity for DNA would be different. According to the gel 
retardation assay, KR displayed the strongest affinity for DNA, followed by PK1 and PK2, 
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whereas LAH4-L1 and NQ had the weakest DNA affinity. As expected, the result reflected that 
the peptides with higher charge density (KR, PK1 and PK2 – all contained classical NLS) 
exhibited a higher DNA binding affinity than those with lower charge density (the unmodified 
LAH4-L1 and the non-classical NLS modified NQ). This is also consistent with the zeta 
potential measurement that the DNA complexes formed with peptides containing classical NLS 
were more positively charged than those formed with LAH4-L1, with KR complexes exhibited 
the highest positive potential. Moreover, the particle size measurement showed that peptides with 
higher DNA binding affinity or at higher peptide to DNA weight ratio (Table S1) tended to form 
DNA complexes with smaller size.  
 
A good balance between DNA binding and release must be maintained in order to allow the 
formation of stable peptide/DNA complexes for effective cellular uptake, as well as the 
dissociation of the complexes inside the cells for DNA transcription to occur. Since effective 
DNA binding was achieved at peptide to DNA ratio of 5:1 (w/w) for all peptides, the subsequent 
transfection study was carried out using complexes prepared at this ratio and above to identify 
the optimal ratio for each peptide. Across the four tested cell lines, for LAH4-L1, the highest 
DNA transfection was achieved at ratio 10:1 to 15:1 (w/w). For peptides containing classical 
NLS (PK1, PK2 and KR), the highest transfection was obtained at a lower ratio of 5:1 to 10:1 
(w/w). For NQ, the highest transfection was observed at ratio 15:1 (w/w). This trend closely 
correlated with the DNA binding affinity of the peptides - the stronger the DNA affinity of the 
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peptides, the smaller the amount of peptide (i.e. lower peptide to DNA ratio) required for 
effective transfection.  
 
Both A549 and Calu-3 cells are human epithelial cancer cell lines that are commonly used for 
evaluating the performance of DNA delivery agents through intranasal or pulmonary 
administration. These routes of administration offer potential advantage of avoiding interaction 
with serum and the rapid nuclease degradation that occurs in the bloodstream.
39
 Compared to 
LAH4-L1, none of the NLS-containing peptides showed significant improvement in gene 
expression on A549 cells. This was not surprising as A549 cells are rapidly dividing cells, 
nuclear uptake of DNA could be achieved easily when the nuclear membrane is disassembled 
during cell mitosis. If the nuclear uptake were not a limiting factor, incorporation of NLS to the 
peptide would not be expected to cause any significant increase in gene expression. Our finding 
is consistent with other studies that report that the contribution of NLS in gene delivery was 
unnecessary or less remarkable in dividing cells.
18, 40
 To examine the role of cell division on 
DNA transfection, A549 cells were growth-arrested by a standard double thymidine blocking 
procedure.
32, 41
 Under such treatment condition, the cells were synchronized and kept at 
non-dividing state, and the transfection results showed that PK1 and PK2 were more efficient in 
mediating DNA transfection than LAH4-L1. Furthermore, PK1 and PK2 were able to 
significantly enhance transfection over the LAH4-L1 on Calu-3 cells. Since Calu-3 cells have a 
much slower cell division rate than A549 cells, the nuclear uptake is inefficient and becomes a 
crucial barrier that impedes the import of DNA into the nucleus. PK1 and PK2 contained the 
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SV40 NLS and ‘reversed’ SV40 NLS respectively, suggesting that SV40 NLS has a role in 
facilitating DNA transfection, possibly by promoting nuclear import in part. However, such an 
improvement was not observed in KR and NQ.  
 
DNA vaccine is an important application of gene therapy, requiring the expression of DNA 
encoding antigen in antigen presenting cells (APCs) to induce sufficient immune responses. The 
potential of the peptides as DNA vaccine carrier was explored. Two APCs were included in this 
transfection study, RAW264.7 cells (macrophages) and JAWSII cells (dendritic cells). Both PK1 
and PK2 outperformed LAH4-L1 on the two cell lines, whereas KR only showed significantly 
better transfection than LAH4-L1 on JAWSII cells. Moreover, PK1, PK2 and KR peptides all 
performed significantly better than Lipofectamine 2000 on JAWSII cells. Combined peptide 
systems containing LAH4-L1 and NLS-modified peptides at different ratios were also examined. 
The rationale of studying the combined peptide system is to optimize the ratio of NLS to DNA 
without changing the total amount of peptides. DNA complexes formed with the combined 
peptide system were around 200 nm or below (Table S2), and the transfection study on JAWSII 
cells showed that all NLS-modified peptides, PK1, PK2 and KR, performed better when used 
alone than in combination with LAH4-L1 (Fig. S1). Dendritic cells are hard to be transfected by 
non-viral vectors. Apart from their slowly dividing property, they are professional APCs that 
strictly control the trafficking of molecules across their cell membranes and difficult to transfer 
genes into the nucleus. Although effective gene transfer was observed using viral vectors, the 
viruses may influence the functions and immune response of the cells which are not desirable.
42, 
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43
 To investigate the safety profile of these peptides and hence their suitability for clinical 
development, cytotoxicity study was performed by measuring the LDH leakage of cells treated 
with the peptide/DNA complexes. LDH is a soluble cytoplasmic enzyme which is released into 
the surrounding medium upon membrane damage or cell lysis. Since LAH4-L1 peptide is 
membrane active at low pH (a mechanism to promote endosomal escape), it is crucial to examine 
the membrane integrity of cells after transfected with LAH4-L1 and its NLS-modified analogues. 
There was no sign of cytotoxicity for PK1, PK2 and KR peptides, indicating that they have the 
potential for further investigation on other antigen-presenting cells as DNA vaccine carriers.  
 
NQ which contains M9 sequence failed to improve the transfection of LAH4-L1 in both 
RAW264.7 and JAWSII cells. Despite the M9 sequence has been reported to improve nuclear 
entry in non-viral vectors,
9, 44-46
 it was not successful in promoting DNA transfection when it was 
incorporated into the LAH4-L1. This lack of activity could be due to the fact that NLS failed to 
be present at the surface of the complexes that render it inaccessible to be recognized by the 
nuclear transport protein transportin, or the size of complexes were too large (above 300 nm) to 
be effectively taken up by the cell through endocytosis. In addition, the highest DNA transfection 
mediated by NQ was obtained at ratio 15:1 (w/w) in all the cell lines tested. Any ratio higher 
than 15:1 (w/w) was not evaluated in this study. An increased amount of NQ may be required to 
show any improvement in DNA delivery. Among the three NLSs being investigated, SV40 
derived NLS demonstrated the biggest improvement of transfection in all tested cell lines apart 
from the rapidly dividing A549 cells and there was no significant difference between SV40 
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derived NLS (PK1) and its reverse sequence (PK2). To gain a better understanding of how SV40 
NLS improved DNA transfection, the cellular and nuclear uptake of DNA was evaluated. 
Peptide/DNA complexes formed at 10:1 ratio (w/w) were selected for the uptake studies due to 
the good transfection efficiency achieved at this ratio across different cell lines, and the peptides 
were able to offer protection against nuclease degradation (Fig. S2). Since PK1 and PK2 carry a 
higher positive charge density than LAH4-L1, and the DNA complexes formed with PK1 and 
PK2 were more positively charged, as shown in the zeta potential measurement, it is possible 
that the modified peptides facilitated cellular entry through the non-specific endocytosis more 
effectively because of the stronger interaction between the cationic complexes and the anionic 
mammalian cell membranes. Also, PK1, PK2 were able to form sub-200 nm DNA complexes, 
whereas the complexes formed with LAH4-L1 were just above 200 nm. Nanoparticles below 200 
nm are usually more effectively taken up by cells through non-specific endocytosis,
47
 which 
could partly explain why PK1 and PK2 were more efficient in mediating DNA transfection.  
 
To explicitly measure the amount of exogenous DNA inside the nucleus, the nuclei of the 
transfected cells were isolated. For cells transfected with PK1 and PK2, the amount of exogenous 
DNA that entered the nucleus was around 1.5-fold and 2-fold higher in RAW264.7 and JAWSII 
cells respectively, than that transfected with LAH4-L1. The confocal imaging study carried out 
on Calu-3 cells revealed the co-localization of fluorescently labelled DNA with nucleus in cells 
transfected with PK2, but not with LAH4-L1, suggesting that nuclear uptake was indeed more 
efficient with PK2. In addition, cells transfected with LAH4-L1, but not PK2, showed some 
Page 32 of 39
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
33 
 
co-localization of DNA with lysosomes, suggested that PK2 might be more effective in 
promoting endosomal/lysosomal escape. Whether the SV40-derived NLS could promote nuclear 
entry through the interaction with importin remain unknown. Further study is required to 
examine the intracellular trafficking of DNA delivered by these peptides. In addition, the 
delivery system could be further optimized by manipulating the number of NLS per molecule of 
carrier peptides. 
 
CONCLUSIONS 
 
In summary, we demonstrated that the pH responsive LAH4-L1 peptide modified with SV40 
derived NLS could significantly enhance DNA transfection in slow dividing cells including 
airway epithelial cells, macrophages, dendritic cells, as well as thymidine-induced 
growth-arrested cells. The improved transfection efficiency of these peptides over LAH4-L1 
could be due to one, or more likely, the combination of the following reasons: (i) enhanced 
cellular uptake; (ii) more efficient endosomal/lysosomal escape; (iii) increased transportation 
across nuclear membrane. The mechanism remains to be elucidated by studying the intracellular 
trafficking and nuclear transportation of the exogenous DNA. The results of this work suggest 
that both PK1 and PK2 peptides are promising DNA carriers and further in vivo investigation is 
warranted. 
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